In a patent infringement lawsuit filed against Eli Lilly, Teva Pharmaceutical won three and lost six patents. The patent lawsuit was over Teva’s Ajovy (fremanezumab-vfrm) to prevent migraines. Eli Lilly has a competitive migraine drug, Emgality (galcanezumab).

United Therapeutics Corporation announced that the company is pursuing additional claims for trade secret misappropriation against Liquidia Technologies Inc. and a former United Therapeutics employee who later joined Liquidia as an executive.

The U.S. Supreme Court rejected Merck & Co. Inc.’s bid to revive a $2.54 billion jury verdict the company won against rival drugmaker Gilead Sciences Inc. for infringing a patent in a dispute over a blockbuster hepatitis C treatment.

Catalyst Pharmaceuticals filed new patent infringement lawsuits against Jacobus Pharmaceuticals and PANTHERx Rare LLC over a treatment for the rare autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS).

Allele Biotechnology and Pharmaceuticals filed lawsuits against Regeneron Pharmaceuticals, as well as Pfizer and Germany’s BioNTech, claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their Covid-19 treatments.

The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict against Teva Pharmaceutical Industries, ordering the company to pay GlaxoSmithKline $235.5 million in a 13-year-old induced patent infringement case.

Biogen filed a lawsuit against a New York life sciences company over alleged patent infringements related to the experimental Alzheimer’s disease treatment aducanumab.

A California jury awarded $752 million to Bristol-Myers Squibb over a patent infringement regarding the technology related to a novel cancer therapy.

A British court ruled in favor of Vectura Group and the company’s partner Sandoz over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

Mallinckrodt shares fell 12% after a U.S. Court of Appeals upheld a federal district court’s decision to reject a patent infringement lawsuit against Praxair’s nitric oxide drug product delivery system.